Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1681 to 1687 of 1687 entries
Sorted by: Best Match Show Resources per page
Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort study.

EClinicalMedicine

Campbell G, Noghrehchi F, Nielsen S, Clare P, Bruno R, Lintzeris N, Cohen M, Blyth F, Hall W, Larance B, Hungerford P, Dobbins T, Farrell M, Degenhardt L.
PMID: 33294810
EClinicalMedicine. 2020 Oct 16;28:100592. doi: 10.1016/j.eclinm.2020.100592. eCollection 2020 Nov.

BACKGROUND: The literature suggests patient characteristics and higher opioid doses and long-term duration are associated with problematic opioid behaviours but no one study has examined the role of all these factors simultaneously in a long-term prospective cohort study.METHODS: Five-year,...

Cite
Campbell G, Noghrehchi F, Nielsen S, et al. Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort study. EClinicalMedicine. 2020;28:100592doi: 10.1016/j.eclinm.2020.100592.
Campbell, G., Noghrehchi, F., Nielsen, S., Clare, P., Bruno, R., Lintzeris, N., Cohen, M., Blyth, F., Hall, W., Larance, B., Hungerford, P., Dobbins, T., Farrell, M., & Degenhardt, L. (2020). Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort study. EClinicalMedicine, 28100592. https://doi.org/10.1016/j.eclinm.2020.100592
Campbell, Gabrielle, et al. "Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort study." EClinicalMedicine vol. 28 (2020): 100592. doi: https://doi.org/10.1016/j.eclinm.2020.100592
Campbell G, Noghrehchi F, Nielsen S, Clare P, Bruno R, Lintzeris N, Cohen M, Blyth F, Hall W, Larance B, Hungerford P, Dobbins T, Farrell M, Degenhardt L. Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort study. EClinicalMedicine. 2020 Oct 16;28:100592. doi: 10.1016/j.eclinm.2020.100592. eCollection 2020 Nov. PMID: 33294810; PMCID: PMC7700907.
Copy Download .nbib Format: NLM
The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors.

Cell chemical biology

Palve V, Knezevic CE, Bejan DS, Luo Y, Li X, Novakova S, Welsh EA, Fang B, Kinose F, Haura EB, Monteiro AN, Koomen JM, Cohen MS, Lawrence HR, Rix U.
PMID: 34329582
Cell Chem Biol. 2021 Jul 22; doi: 10.1016/j.chembiol.2021.07.008. Epub 2021 Jul 22.

PARP inhibitors (PARPis) display single-agent anticancer activity in small cell lung cancer (SCLC) and other neuroendocrine tumors independent of BRCA1/2 mutations. Here, we determine the differential efficacy of multiple clinical PARPis in SCLC cells. Compared with the other PARPis...

Cite
Palve V, Knezevic CE, Bejan DS, et al. The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors. Cell Chem Biol. 2021;doi: 10.1016/j.chembiol.2021.07.008.
Palve, V., Knezevic, C. E., Bejan, D. S., Luo, Y., Li, X., Novakova, S., Welsh, E. A., Fang, B., Kinose, F., Haura, E. B., Monteiro, A. N., Koomen, J. M., Cohen, M. S., Lawrence, H. R., & Rix, U. (2021). The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors. Cell chemical biology, . https://doi.org/10.1016/j.chembiol.2021.07.008
Palve, Vinayak, et al. "The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors." Cell chemical biology vol. (2021). doi: https://doi.org/10.1016/j.chembiol.2021.07.008
Palve V, Knezevic CE, Bejan DS, Luo Y, Li X, Novakova S, Welsh EA, Fang B, Kinose F, Haura EB, Monteiro AN, Koomen JM, Cohen MS, Lawrence HR, Rix U. The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors. Cell Chem Biol. 2021 Jul 22; doi: 10.1016/j.chembiol.2021.07.008. Epub 2021 Jul 22. PMID: 34329582.
Copy Download .nbib Format: NLM
Efficacy of baricitinib for refractory large-vessel vasculitis.

Rheumatology (Oxford, England)

Régent A, Terrier B, Legendre P, Wartski M, Cohen P, Mouthon L, Le Jeunne C.
PMID: 34247230
Rheumatology (Oxford). 2021 Nov 03;60(11):e389-e391. doi: 10.1093/rheumatology/keab541.

No abstract available.

Cite
Régent A, Terrier B, Legendre P, et al. Efficacy of baricitinib for refractory large-vessel vasculitis. Rheumatology (Oxford). 2021;60(11):e389-e391doi: 10.1093/rheumatology/keab541.
Régent, A., Terrier, B., Legendre, P., Wartski, M., Cohen, P., Mouthon, L., & Le Jeunne, C. (2021). Efficacy of baricitinib for refractory large-vessel vasculitis. Rheumatology (Oxford, England), 60(11), e389-e391. https://doi.org/10.1093/rheumatology/keab541
Régent, Alexis, et al. "Efficacy of baricitinib for refractory large-vessel vasculitis." Rheumatology (Oxford, England) vol. 60,11 (2021): e389-e391. doi: https://doi.org/10.1093/rheumatology/keab541
Régent A, Terrier B, Legendre P, Wartski M, Cohen P, Mouthon L, Le Jeunne C. Efficacy of baricitinib for refractory large-vessel vasculitis. Rheumatology (Oxford). 2021 Nov 03;60(11):e389-e391. doi: 10.1093/rheumatology/keab541. PMID: 34247230.
Copy Download .nbib Format: NLM
Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Ruetsch-Chelli C, Bresch S, Seitz-Polski B, Rosenthal A, Desnuelle C, Cohen M, Brglez V, Ticchioni M, Lebrun-Frenay C.
PMID: 33768513
Neurotherapeutics. 2021 Apr;18(2):938-948. doi: 10.1007/s13311-021-01006-9. Epub 2021 Mar 25.

Myasthenia gravis can be efficiently treated with rituximab but there is no consensus regarding administration and dose schedules in this indication. No marker has yet been described to predict the clinical relapse of patients. Our objective was to identify...

Cite
Ruetsch-Chelli C, Bresch S, Seitz-Polski B, et al. Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis. Neurotherapeutics. 2021;18(2):938-948doi: 10.1007/s13311-021-01006-9.
Ruetsch-Chelli, C., Bresch, S., Seitz-Polski, B., Rosenthal, A., Desnuelle, C., Cohen, M., Brglez, V., Ticchioni, M., & Lebrun-Frenay, C. (2021). Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 18(2), 938-948. https://doi.org/10.1007/s13311-021-01006-9
Ruetsch-Chelli, Caroline, et al. "Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis." Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics vol. 18,2 (2021): 938-948. doi: https://doi.org/10.1007/s13311-021-01006-9
Ruetsch-Chelli C, Bresch S, Seitz-Polski B, Rosenthal A, Desnuelle C, Cohen M, Brglez V, Ticchioni M, Lebrun-Frenay C. Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis. Neurotherapeutics. 2021 Apr;18(2):938-948. doi: 10.1007/s13311-021-01006-9. Epub 2021 Mar 25. PMID: 33768513; PMCID: PMC8423951.
Copy Download .nbib Format: NLM
'No place like home?' A qualitative study of the experience of sense of place among cancer patients near the end of life.

Health & social care in the community

Ivzori Erel A, Cohen M.
PMID: 34322935
Health Soc Care Community. 2021 Jul 29; doi: 10.1111/hsc.13526. Epub 2021 Jul 29.

Only a few studies have examined the end-of-life experience in the context of the place of living and receiving care. Sense of place consists of emotional bonds, values, meaning, and symbols attached to a place. This study aimed to...

Cite
Ivzori Erel A, Cohen M. 'No place like home?' A qualitative study of the experience of sense of place among cancer patients near the end of life. Health Soc Care Community. 2021;doi: 10.1111/hsc.13526.
Ivzori Erel, A., & Cohen, M. (2021). 'No place like home?' A qualitative study of the experience of sense of place among cancer patients near the end of life. Health & social care in the community, . https://doi.org/10.1111/hsc.13526
Ivzori Erel, Adi, and Cohen, Miri. "'No place like home?' A qualitative study of the experience of sense of place among cancer patients near the end of life." Health & social care in the community vol. (2021). doi: https://doi.org/10.1111/hsc.13526
Ivzori Erel A, Cohen M. 'No place like home?' A qualitative study of the experience of sense of place among cancer patients near the end of life. Health Soc Care Community. 2021 Jul 29; doi: 10.1111/hsc.13526. Epub 2021 Jul 29. PMID: 34322935.
Copy Download .nbib Format: NLM
Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial.

Alzheimer's & dementia (Amsterdam, Netherlands)

Ngolab J, Donohue M, Belsha A, Salazar J, Cohen P, Jaiswal S, Tan V, Gessert D, Korouri S, Aggarwal NT, Alber J, Johnson K, Jicha G, van Dyck C, Lah J, Salloway S, Sperling RA, Aisen PS, Rafii MS, Rissman RA.
PMID: 34430703
Alzheimers Dement (Amst). 2021 Aug 17;13(1):e12199. doi: 10.1002/dad2.12199. eCollection 2021.

INTRODUCTION: The retina and brain exhibit similar pathologies in patients diagnosed with neurodegenerative diseases. The ability to access the retina through imaging techniques opens the possibility for non-invasive evaluation of Alzheimer's disease (AD) pathology. While retinal amyloid deposits are...

Cite
Ngolab J, Donohue M, Belsha A, et al. Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial. Alzheimers Dement (Amst). 2021;13(1):e12199doi: 10.1002/dad2.12199.
Ngolab, J., Donohue, M., Belsha, A., Salazar, J., Cohen, P., Jaiswal, S., Tan, V., Gessert, D., Korouri, S., Aggarwal, N. T., Alber, J., Johnson, K., Jicha, G., van Dyck, C., Lah, J., Salloway, S., Sperling, R. A., Aisen, P. S., Rafii, M. S., & Rissman, R. A. (2021). Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial. Alzheimer's & dementia (Amsterdam, Netherlands), 13(1), e12199. https://doi.org/10.1002/dad2.12199
Ngolab, Jennifer, et al. "Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial." Alzheimer's & dementia (Amsterdam, Netherlands) vol. 13,1 (2021): e12199. doi: https://doi.org/10.1002/dad2.12199
Ngolab J, Donohue M, Belsha A, Salazar J, Cohen P, Jaiswal S, Tan V, Gessert D, Korouri S, Aggarwal NT, Alber J, Johnson K, Jicha G, van Dyck C, Lah J, Salloway S, Sperling RA, Aisen PS, Rafii MS, Rissman RA. Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial. Alzheimers Dement (Amst). 2021 Aug 17;13(1):e12199. doi: 10.1002/dad2.12199. eCollection 2021. PMID: 34430703; PMCID: PMC8369843.
Copy Download .nbib Format: NLM
Educational Outcomes of the Harvard Medical School-Cambridge Integrated Clerkship: A Way Forward for Medical Education.

Krupat E, Gaufberg E, Hirsh D, Ogur B, Pelletier S, Bor D, Cohen P, Cox M.
UIID-AD: 469
2012;87:643-650. doi: 10.1097/ACM.0b013e31824d9821.

Purpose The authors report data from the Harvard Medical School-Cambridge Integrated Clerkship (CIC), a model of medical education in which students' entire third year consists of a longitudinal, integrated curriculum. The authors compare the knowledge, skills, and attitudes of...

Cite
Krupat E, Gaufberg E, Hirsh D, et al. Educational Outcomes of the Harvard Medical School-Cambridge Integrated Clerkship: A Way Forward for Medical Education. 2012;87:643-650doi: 10.1097/ACM.0b013e31824d9821.
Krupat, E., Gaufberg, E., Hirsh, D., Ogur, B., Pelletier, S., Bor, D., Cohen, P., & Cox, M. (2012). Educational Outcomes of the Harvard Medical School-Cambridge Integrated Clerkship: A Way Forward for Medical Education. 87643-650. https://doi.org/10.1097/ACM.0b013e31824d9821
Krupat, E, et al. "Educational Outcomes of the Harvard Medical School-Cambridge Integrated Clerkship: A Way Forward for Medical Education." vol. 87 (2012): 643-650. doi: https://doi.org/10.1097/ACM.0b013e31824d9821
Krupat E, Gaufberg E, Hirsh D, Ogur B, Pelletier S, Bor D, Cohen P, Cox M. Educational Outcomes of the Harvard Medical School-Cambridge Integrated Clerkship: A Way Forward for Medical Education. 2012;87:643-650. doi: 10.1097/ACM.0b013e31824d9821. UIID-AD: 469.
Copy Download .nbib Format: NLM
Showing 1681 to 1687 of 1687 entries